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Abstract
Background: Immunotherapy for patients with microsatellite‐instable (MSI‐H) tu-
mors or BRAF‐inhibitors combination treatment for BRAF‐mutated (mutBRAF) tu-
mors in metastatic colorectal cancer (mCRC) is promising, but the frequency of these 
molecular changes in trial patients are low. Unselected population‐based studies of 
these molecular changes are warranted.
Methods: A population‐based cohort of 798  mCRC patients in Scandinavia was 
studied. Patient and molecular tumor characteristics, overall survival (OS) and pro-
gression‐free survival (PFS) were estimated.
Results: Here, 40/583 (7%) tumor samples were MSI‐H and 120/591 (20%) were 
mutBRAF; 87% of MSI‐H tumors were mutBRAF (non‐Lynch). Elderly (>75 years) 
had more often MSI‐H (10% vs 6%) and MSI‐H/mutBRAF (9% vs 4%) tumors. 
Response rate (5% vs 44%), PFS (4 vs 8 months), and OS (9 vs 18 months) after first‐
line chemotherapy was all significantly lower in patients with MSI‐H compared to 
patients with microsatellite stable tumors. MSI‐H and mutBRAF were both independ-
ent poor prognostic predictors for OS (P = 0.049, P < 0.001) and PFS (P = 0.045, 
P = 0.005) after first‐line chemotherapy. Patients with MSI‐H tumors received less 
second‐line chemotherapy (15% vs 37%, P = 0.005).
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1 |  BACKGROUND
Colorectal cancer (CRC) is a heterogeneous group of tumors 
with a wide range of genetic changes. Microsatellite insta-
bility (MSI) is caused by mutations in DNA mismatch repair 
(MMR) genes, which leads to failure to repair errors that occur 
in DNA replication in repetitive sequences (microsatellites). 
This leads to accumulation of frameshift mutations in genes 
with microsatellites, also called MSI‐high (MSI‐H). Most 
MSI‐H tumors result from accumulated mutations during 
life but can also occur due to inherited MMR deficiency 
(Lynch syndrome). Most previous studies on metastatic CRC 
(mCRC) have reported that around 4% of the tumors are 
MSI‐H1-5 and 5%‐12% BRAF mutated (mutBRAF).3,4,6,7 Most 
previous reports are based on patients included in clinical tri-
als, and these patients are highly selected with both younger 
age and better performance status (PS) compared to patients 
in the general clinical practice.8,9 Sporadic MSI‐H CRC is 
associated with a BRAF mutation in about 40%‐60% of the 
cases, whereas Lynch syndrome tumors are essentially BRAF 
wild‐type (wtBRAF).10,11 In nonmetastatic CRC, MSI‐H is 
associated with less risk of recurrence and improved sur-
vival compared to microsatellite stable (MSS) tumors.12,13 In 
mCRC, MSI‐H tumors appear to have poor prognosis, but the 
number of patients in these studies are limited.2-6,14 However, 
mutBRAF has a strong negative prognostic impact in mCRC, 
but the possible relevance of MSI status for poor prognosis is 
not clarified.3-6,15-17
Recent studies have shown that mCRC patients with 
MSI‐H tumors respond to immunotherapy given mainly 
as third‐line treatment.18-20 The recently updated National 
Comprehensive Cancer Network guidelines recommend 
second‐line treatment with a PD‐1 inhibitor in patients with 
MSI‐H tumor and addition of BRAF‐inhibitors to standard 
treatment in patients with mutBRAF tumors.21 For these rea-
sons, it is important to know the proper frequency, clinical 
characteristics, prognosis and treatment response in patients 
with MSI‐H and mutBRAF tumors in population‐based co-
horts. The aim of this study was to analyze MSI‐status in re-
lation to clinical and pathological variables, mutBRAF status 
and survival in a population‐based cohort of mCRC.
2 |  MATERIALS AND METHODS
2.1 | Patient cohort
The study cohort is a prospective registration of non‐resect-
able mCRC patients referred to the oncology units of three uni-
versity hospitals in Scandinavia (Odense University Hospital 
in Denmark, Uppsala University Hospital in Sweden and 
Haukeland University Hospital in Norway) between October 
2003 and August 2006. Cases not referred (n = 49) were iden-
tified via the regional cancer registries. This cohort therefore 
includes all patients diagnosed with nonresectable mCRC in 
these three Nordic geographical regions. A total of 798 patients 
were included.7 The clinical data is from date of inclusion and 
was obtained from case report forms filled in by clinicians.
2.2 | Tissue retrieval and tissue 
microarray generation
Paraffin‐embedded tissue blocks of the primary tumor or 
from a metastatic lesion were retrieved and correspond-
ing hematoxylin‐eosin stained glass slides were examined. 
Tumor tissue from 462 cases (58%) was available for initial 
tissue microarray (TMA cohort) construction as described 
previously7 according to standards used in the Human 
Protein Atlas.22 DNA was extracted from the tissue cores 
using Recoverall Total Nucleic Acid Isolation (Ambion, 
Austin, TX). In the present study we supply additional analy-
ses from patients without enough tumor material for TMA/
DNA analysis (167 patients), called the immunohistochem-
istry (IHC) cohort. Totally 604 cases had tumor tissue avail-
able for analysis, as 25 cases failed due to technical reasons 
(Supplementary Figure S1).
2.3 | Tumor analyses
BRAF and KRAS analyses of the TMA cohort had been done 
previously by pyrosequencing mutational analysis with 5% 
mutation signal as cut off, and the use of PCR primers for 
KRAS codon 12/13 and BRAF codon 600.7 MSI status for 
BRAF‐mutated patients in the TMA cohort had previously been 
Conclusions: In unselected mCRC patients, MSI‐H and mutBRAF cases were more 
common than previously reported. Patients with MSI‐H tumors had worse survival, less 
benefit from chemotherapy, and they differed considerably from recent third‐line immu-
notherapy trial patients as they were older and most had mutBRAF tumor (non‐Lynch).
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obtained by DNA analysis using MSI Analysis System, version 
1.2 (Promega, Madison, WI) with 6 ng genomic DNA.7
Immunohistochemistry (IHC) and image acquisition 
was performed according to standards used within the 
Human Protein Atlas.23  TMA sections 4 mm thick were 
subjected to heat‐induced antigen retrieval using PT mod-
ule buffer 1 (pH 6, ThermoScientific) in a Decloaking 
Chamber (Biocare Medical), except for BRAF stained 
with special protocol HIER with TRIS‐EDTA at pH8. 
Automated IHC was performed using a LabVision 
Autostainer 480S (Thermo Fisher Scientific, Runcorn, 
UK). BRAF mutation was assessed with mouse antibody 
from Spring Bioscience, E19292, Clone VE1, diluted 
1:50. MSH‐2 and MLH‐1 with mouse antibody from 
Becton Dickinson and Company (formerly PharMingen), 
Clone  =  G219‐1129 and G168‐15, diluted 1:200 and 
1:100, respectively. PMS‐2 and MSH‐6 with rabbit anti-
body from Abcam plc, ab110638 clone  =  EPR3947 and 
ab92471 clone  =  EPR3945, diluted 1:75 and 1:125 re-
spectively. IHC for V600E BRAF mutation was analyzed 
in both TMA and IHC cohorts. Cytoplasmic staining for 
BRAF mutation was qualitatively scored as positive (mu-
tated) or negative (wildtype) in tumor cells. The results 
from the IHC and DNA analysis were compared and found 
inconsistent in seven cases. One of them had a V600R 
mutation discovered by sequencing and obviously not de-
tected by the V600E IHC analysis. This patient was de-
fined as mutBRAF. One patient turned out to be mutBRAF 
according to pyrosequencing, but wtBRAF according to 
IHC evaluation. This case had low amount of mutated 
DNA (8%), was mutKRAS and was therefore considered 
wtBRAF. The other five patients with inconsistent results 
were excluded from further analysis. A final BRAF sta-
tus conclusion was made in 591 patients (Supplementary 
Figure S1 and Figure S2).
IHC for expression of MLH1, PMS2, MSH2, and MSH6 
was performed for all patients included in the TMA cohort. 
Only MSH6 and PMS2 was analyzed in the additional IHC 
cohort due to limited amount of material in most cases. 
Nuclear fraction (NF) of the four MMR proteins were es-
timated. The samples were denoted as deficient DNA mis-
match repair (dMMR) if complete loss of PMS2 or MSH6 
staining. One patient had complete loss of MSH2 staining, 
but clearly positive staining for PMS2. This is an unexpected 
finding and the patient was therefore excluded from the final 
analysis. Results from IHC and DNA analysis were compared 
and merged, further referred to as MSI‐H or MSS, in 583 
patients (Supplementary Figure S1).
2.4 | Statistics
Group comparisons were performed using the exact chi‐
square test for dichotomous or nominal variables and the 
log‐rank test for survival times. Multiple binary logistic 
regression was used for dichotomous outcome variables. 
Results are reported as odds ratios (ORs) and 95% confi-
dence intervals (CIs). Overall survival time (OS) was the 
interval from the date of metastatic disease to the date of 
death or censored if the patient was alive on February 4, 
2014. Progression‐free survival (PFS) was the interval from 
the date of first administration of chemotherapy to the date 
of progression (on CT scan) or death or censored if the pa-
tient was alive without progression on February 4, 2014. OS 
and PFS were analyzed using the Kaplan‐Meier method and 
Cox multiple regression. For the multivariate survival analy-
ses we used Cox regression and backward stepwise selec-
tion of covariates to the final model. At the first step, we 
included all relevant covariates. These were prognostic vari-
ables for mCRC patients as recommended by Goey et al,24 
only excluding the volume of liver involvement as this was 
not available. In addition, we included tumor grade, female 
sex and high alkaline phosphatase in blood samples as these 
variables are prognostic markers for survival. CEA >4 µg/L 
and high LDH were statistically significant when included 
in the multiple regression model, but were excluded from 
the analysis due to many missing values. From this model, 
we removed the variable with the largest P‐value >0.05. In 
the second step, we removed the covariate with the largest 
P > 0.05 among the remaining variables from the first step. 
The process continued until all the remaining variables were 
significant at level 0.05 and a final model was obtained. 
Results are reported as hazard ratios (HRs) and 95% CIs. All 
analyses were performed with the statistical program SPSS 
v22. All statistical tests were two‐tailed using significance 
level 5%.
3 |  RESULTS
3.1 | Study population
In the 604 patients with sufficient morphological material 
of invasive adenocarcinoma for analyses (Supplementary 
Figure S1), the median age was 70 years and 209 patients 
(35%) were >75 years. In total 215 patients (36%) had PS 
>1. First‐line chemotherapy was given to 377 patients (62%, 
75% below 75 years, and 26% above). Of those, 287 patients 
(76%) received combination chemotherapy, 28 patients (7%) 
received bevacizumab, and 27 patients (7%) received an 
EGFR‐inhibitor. Supplementary Table S1 illustrates follow‐
up data on frequency of second‐ and third‐line treatment ac-
cording to the different first‐line treatment given. Median 
OS (95% CI) was 11 months (9.6‐12.3) for all patients. For 
patients treated with first‐line chemotherapy, median OS 
and PFS were 17  months (15.0‐19.0) and 8  months (7.2, 
8.4), respectively. At last follow‐up, 24 patients (3%) were 
alive.
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3.2 | MSI, BRAF status, and patient 
characteristics
Totally 40 (7%) of 583 evaluable tumors were MSI‐H. 
Tumors with MSI‐H status had more often mutBRAF com-
pared to MSS tumors (87% vs 16%, P < 0.001), and conse-
quently less often KRAS mutations (mutKRAS) (6% vs 44%, 
P < 0.001). Figure 1A illustrates KRAS, BRAF, and MSI sta-
tus in the TMA cohort (n = 428). MSI‐H patients had less 
often liver and lung metastases, but more often lymph node 
metastases (Table 1). Female sex, right‐sided primaries, el-
derly patients, and grade 3‐4 tumors were more common in 
the MSI‐H group. Patients with MSI‐H tumors given first‐
line palliative chemotherapy received less often second‐ and 
third‐line chemotherapy compared to MSS (30% vs 58%, 
P = 0.019 and 5% vs 27%, P = 0.033, respectively). In fully 
adjusted multiple logistic regression, right‐sided primaries, 
mutBRAF, and no lung metastases were significantly associ-
ated with MSI‐H status (Supplementary Table S2).
When analyzing all 591 patients with BRAF status avail-
able, the frequency of mutBRAF was 20% (120 of 591 pa-
tients) and MSI‐H was 7%. Tumors with mutBRAF were 
more often MSI‐H compared to wtBRAF (28% vs 1%, 
P < 0.001). We divided the patients into four groups ac-
cording to MSI/BRAF status (Figure 1B, Supplementary 
Table S3). Elderly patients (>75  years) had more often 
MSI‐H/mutBRAF tumors compared to patients <75 years 
(9% vs 4%, P  =  0.012). Patients with MSI‐H/mutBRAF 
tumors had also more often lymph node metastases and 
tumor grade 3, but less often liver metastases compared 
to the other groups. Patients with MSI‐H/wtBRAF tumors 
had more often liver metastasis as well as liver‐only metas-
tasis compared to the other groups.
3.3 | Overall and progression‐free survival
Both median OS and PFS were shorter in patients with 
MSI‐H tumors (Figure 2, Table 2, Figure 3). Median OS was 
6 months for patients with MSI‐H compared to 11 months for 
patients with MSS tumors (P = 0.004). Patients with mut-
BRAF tumors had a median OS of 7  months compared to 
12 months with wtBRAF tumors (P < 0.001). Median OS in 
elderly patients was 4 versus 5 months for MSI‐H vs MSS 
cases (P = 0.024) and 3 versus 6 months (P < 0.001) for mut-
BRAF versus wtBRAF cases, respectively. For patients <75 
years, median OS was 8 versus 15 months (P = 0.012) for 
MSI‐H vs MSS cases and 11 versus 16 months (P < 0.001) 
for mutBRAF vs wtBRAF patients, respectively. In the best 
supportive care group, median OS was 2 versus 3  months 
for MSI‐H versus MSS patients, respectively (P  =  0.025). 
Among patients given first‐line chemotherapy, median 
OS was 9 versus 18  months for MSI‐H versus MSS cases 
(P = 0.010), and 13 versus 18 months for mutBRAF vs wt-
BRAF cases (P = 0.005). Median PFS after 1st‐line chem-
otherapy was 4 versus 8  months for MSI‐H versus MSS 
cases (P = 0.101) and 7 versus 8 months for mutBRAF ver-
sus wtBRAF cases (P = 0.125). For patients with response 
registered after first‐line chemotherapy with the MSI status 
(n = 321) and BRAF status (n = 328) available, the objective 
response rate (ORR) was 5% versus 44% for MSI‐H versus 
MSS cases (P = 0.002), and 37% versus 43% for mutBRAF 
versus wtBRAF cases (P = 0.609).
In log‐rank survival analyses, the negative prognostic 
potential of MSI‐H was only statistically significant in 
wtBRAF tumors and the negative prognostic potential of 
mutBRAF was only seen in MSS tumors (Figure 4A‐D, 
supplementary Figure S3). The test of interaction between 
these two variables was significant (P = 0.010), also when 
F I G U R E  1  Mutation status in a 
population‐based Scandinavian cohort of 
metastatic colorectal cancer: (A) Venn 
diagram illustrating KRAS, BRAF and 
MSI status in primary tumors of patients 
in the TMA cohort with analysis available 
(n = 428), (B) Distribution of BRAF/
MSI subgroups in patients with sufficient 
material for these analyses (n = 569), (C) 
Incidence (%) of BRAF mutations in MSI‐H 
tumors in the Scandinavian prospective 
colorectal cancer cohort (SPCRC) 
(n = 40) compared to recently published 
immunotherapy trials by Le et al 2015 
(n = 21), Overman et al 2017 (n = 74) and 
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adjusting for other prognostic variables (P = 0.037, Table 
3). When dividing patients into four subgroups according 
to BRAF and MSI status, median OS and PFS after first‐
line chemotherapy was statistically significantly different 
(Figure 4E‐G, Table 2). Patients with MSI‐H/wtBRAF had 
the worst prognosis compared to the other groups with only 
2  months median OS and PFS, but we had only five pa-
tients with this molecular tumor characteristic. The nega-
tive prognostic value of MSI‐H status was seen regardless 
of KRAS status, and in patients with wild‐type KRAS and 
wtBRAF (double wildtype) tumors, but we had very few 
patients in some of the subgroups (Supplementary Table 
S4).
In multiple Cox regression analyses, including known 
clinical prognostic factors for mCRC survival, mutBRAF was 
the only molecular tumor marker significantly associated 
with reduced OS. For patients who received first‐line che-
motherapy mutBRAF, mutKRAS and MSI‐H were all signifi-
cantly associated with shorter OS and PFS (Table 3).
4 |  DISCUSSION
This is, as far as we know, the largest population‐based 
study reporting on MSI and BRAF status and its effect on 
treatment and survival in mCRC. The general poor survival 
in our cohort is comparable to that seen in Scandinavian 
cancer registries (10  months median OS) (8) and the 
American SEER database (1 year survival rate 47%) 25 dur-
ing the same time period, reflecting our real‐world cohort 
of patients and not poor treatment, as patients receiving 
combination chemotherapy had the same OS as in clini-
cal trials, including patients during the same time period. 
We report 7% MSI‐H tumors, almost twice as high as most 
previous reports of mCRC.1-5 We believe this is due to the 
unselected nature of the cohort with many elderly patients, 
patients with poor PS, never included in clinical trials, 
and many mutBRAF cases. Tran et al observed 8% MSI‐H 
in a trial population group and 13% in a general popula-
tion group, also showing higher presence of MSI‐H in pa-
tients outside clinical trials.6 A recently published study 
on genomic profiling of 8887 mCRC patients reported 7% 
MSI‐H cases,26 in accordance with our result. In this study, 
we also confirm our previously published result showing 
a much higher frequency of mutBRAF tumors (20%) com-
pared to previous studies.7 The same frequency is reported 
in a recent Nordic phase II trial of elderly vulnerable pa-
tients with mCRC.27 The relatively higher frequency of 
MSI‐H and mutBRAF in the general mCRC population im-
plicates that more patients than previously expected could 
benefit from immunotherapy, or being candidate for adding 
BRAF‐inhibitor combinations to standard treatment (Figure 
3). This stresses the importance of MMR and BRAF testing 
in all mCRC patients. Figure 3 illustrates the distribution of 
the tumor molecular alterations, their survival and possible 
treatment options.
F I G U R E  2  Survival in a population‐
based Scandinavian cohort of patients with 
metastatic colorectal cancer according 
to MSI status. Kaplan‐Meier curves was 
calculated with log‐rank test for p‐value 
and univariate Cox regression for HR and 
95% CI. A, Median overall survival for 
all patients with MSI status was 6 mo for 
patients with MSI‐H tumors and 11 mo 
for patients with MSS tumors. B, Median 
overall survival in patients given first‐line 
chemotherapy was 9 mo for patients with 
MSI‐H tumors and 18 mo for patients 
with MSS tumors. C, Median progression 
free survival in patients given first‐line 
chemotherapy was 4 mo for patients with 
MSI‐H tumors and 8 mo for patients with 
MSS tumors. n, number of patients; e, 
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In primary, non‐metastatic CRC, MSI‐H is known to be 
a good prognostic factor.28,29 In mCRC, on the other hand, 
these patients belong to the poor prognostic group, in accor-
dance with previous studies.2,3,5,6,14 MSI‐H and mutBRAF 
were clearly associated, and in multivariate analysis both 
tumor markers were independent poor prognostic predictors 
for OS and PFS in patients treated with first‐line chemother-
apy. In subgroup analysis, we found that the negative impact 
of MSI‐H on survival only reached statistical significance in 
wtBRAF patients, and the negative impact of mutBRAF on 
survival was only seen in MSS patients. Previous studies on 
this matter have shown contradictory results.3-6,16,30 None of 
the other studies are entirely population based, and a limita-
tion of all studies, including our own, is the limited number 
of patients in some subgroups. In our cohort, patients with 
MSI‐H/wtBRAF tumors had the worst prognosis, in accor-
dance with the randomized COIN trial.3 A recent study re-
ports poor prognosis in mCRC patients with ALK, ROS1, 
and NTRK rearrangements in tumor, and these cases were 
associated with MSI‐H (48%) and were almost exclusively 
wtBRAF (96%).31 This might explain the particularly poor 
prognosis we see in this subpopulation, but the very limited 
number of patients in this group precludes firm conclusions 
and the results need verification in the larger studies.
Our cohort of MSI‐H patients had substantially less ben-
efit from chemotherapy compared to MSS patients, and very 
few made it to the second‐ and third‐line of treatment. Recent 
third‐line immunotherapy trials in MSI‐H mCRC patients 
have shown ORR 31% (nivolumab monotherapy) and 55% 
(dual checkpoint inhibition), with median PFS and OS not 
reached at 12 months.19,20 These impressive results are in great 
contrast to the treatment benefit (ORR 5%, PFS 4 months) 
and survival (OS 9 months) seen in our unselected MSI‐H pa-
tients treated with first‐line chemotherapy. However, the pa-
tient populations differ greatly and there are probably several 
reasons for this vast difference in prognosis. More than 45% 
of our MSI‐H patients had PS > 1, while immunotherapy tri-
als only include patients with PS 0‐1. Most MSI‐H patients in 
our cohort were also mutBRAF (87%) (Figure 1C), markedly 
in contrast to the immunotherapy trials, where only 0%, 16%, 
and 24% were mutBRAF18-20 (Figure 1D‐F). Other popula-
tion‐based cohorts of mCRC have shown different frequen-
cies of mutBRAF in MSI‐H tumors, ranging from 25%‐60%, 
but with limited number of patients.4,6,16,29,32 Patients with 
Lynch syndrome tumors are essentially MSI‐H/wtBRAF and 
often diagnosed at a younger age, which could explain the 
high frequency of these patients in clinical studies. In our 
study, we found only five cases with this molecular feature. 
MSI‐H/mutBRAF tumors develop in the serrated pathway 
and belong to the consensus molecular subtype 1 classifica-
tion of CRC, associated with poor survival after relapse.33 In 
the two immunotherapy trials including patients with mut-
BRAF tumors, the response rate and survival did not signifi-
cantly differ according to BRAF status, but the numbers were 
limited. Additional data on immunotherapy in the non‐Lynch 
group in a general patient population is warranted, to further 
evaluate if the benefit of immunotherapy in MSI‐H patients 
may vary according to BRAF status.
In our study, MSI‐H/mutBRAF cases were more often 
seen in elderly patients (>75  years), and median age of 
MSI‐H cases was 75 years, in great contrast to the recent 
third‐line immunotherapy trials (46‐58 years).18-20 MSI‐H 
status was less important for survival in elderly patients, 
but this might in part reflect the low treatment frequency 
in this subgroup. Elderly cancer patients in general receive 
less palliative chemotherapy and treatment recommenda-
tions for the elderly are uncertain as they usually are not 
included in clinical trials.8 In a recent retrospective study, 
elderly patients (>62  years) with malignant melanoma 
had a better response to anti‐PD‐1 therapy compared to 
younger patients,34 believed to be due to decreased intertu-
moral Tregs and increased CD8+:Treg ratio in the elderly 
patients. Considering the high age of most mCRC patients 
with MSI‐H tumors, future studies on immunotherapy in 
elderly patients are important.
The marked difference between our MSI‐H patients and 
third‐line immunotherapy trials reported so far should be 
taken into consideration when transferring results from these 
studies to the general population. There is reason to believe 
F I G U R E  3  Frequency of molecular alterations and survival 
data after first‐line chemotherapy in a Scandinavian population‐based 
cohort of metastatic colorectal cancer (SPCRC) with suggestions on 
choice of treatment for the specific patient groups. Double wildtype, 
BRAF and KRAS wildtype; mutBRAF, BRAF mutation; mutKRAS, 
KRAS mutation; MSI‐H, microsatellite instability‐high; OS, median 
overall survival; PFS, median progression‐free survival; CI, confidence 
interval; †) after first‐line chemotherapy
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that future immunotherapy trials in first‐line may recruit a 
more heterogeneous MSI‐H population, with for instance 
more aggressive disease and more mutBRAF cases.
At present, the use of immune‐checkpoint inhibitors is 
recommend as second‐line treatment for MSI‐H mCRC pa-
tients.21 Our data, however, show that a substantial number 
of MSI‐H patients never get to second‐line treatment and the 
benefit of first‐line chemotherapy is very limited. Both these 
factors indicate that checkpoint inhibitors should probably 
be given as first‐line treatment and such studies are ongo-
ing. A recent abstract from the Checkmate 142 trial with 
first‐line dual checkpoint inhibition in 45 patients reported 
60% ORR, in line with third‐line immunotherapy trials.35 
The very poor response rate in our cohort of 5% in MSI‐H 
compared to 40% in MMS is of particular concern if the 
patient has a potentially resectable disease, and first‐line 
treatment with checkpoint inhibitors should be considered 
in such cases.
F I G U R E  4  Survival in a population‐based Scandinavian cohort of metastatic colorectal cancer patients according to MSI and BRAF status. 
Kaplan‐Meier curves was calculated with log‐rank test for p‐value and univariate Cox regression for HR and 95% CI. A, Median overall survival 
for patients with MSS tumors was 8 mo if mutBRAF and 12 mo if wtBRAF. B, Median overall survival for patients with MSI‐H tumors was 6 mo 
if mutBRAF and 2 mo if wtBRAF. C, Median overall survival for patients with BRAF-wildtype tumors was 2 mo if MSI‐H and 12 mo if MSS. D, 
Median overall survival for patients with BRAF‐mutated tumors was 6 mo if MSI‐H and 8 mo if MSS. E, Median overall survival for all patients in 
subgroups of MSI and BRAF status. F, Median overall survival for patients given first‐line chemotherapy. G, Median progression free survival for 
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5 |  LIMITATIONS OF STUDY
This is a prospectively collected study; the analyses, how-
ever, were done retrospectively. The patients were treated 
more than 10 years ago, and although the treatment options 
for mCRC have not changed much in the past decade, we 
possibly treat more patients with more intensive/combination 
regimens as well as metastasectomy, resulting in improved 
survival. Our study is population‐based and therefore in-
cludes more patients with older age, worse PS, comorbidity 
and less treatment compared to clinical trials, however, pa-
tients without available or sufficient tumor tissue for analysis 
could not be included and these patients have a particularly 
poor prognosis.7 Despite this being the largest population‐
based study reporting on MSI and BRAF status and its effect 
on survival in mCRC, the number of patients in some of the 
MSI/BRAF subgroups was still limited.
6 |  CONCLUSIONS
In a population‐based cohort of mCRC patients, MSI‐H 
and mutBRAF were more common than previously re-
ported, and consequently more patients could benefit from 
T A B L E  3  Results from multiple Cox regression of overall survival and progression free survival in a population-based Scandinavian cohort 
of metastatic colorectal cancer patients (n = 798) diagnosed from October 2003 to August 2006 and followed until 4 February 2014
 
Overall survival all patientsa) 
(n = 360, e = 343)
Overall survival in patients given 
1st‐line chemotherapy (n = 248, 
e = 233)
Progression free survival after 
1st‐line chemotherapy (n = 247, 
e = 237)
Variable HR 95% CI P‐value HR 95% CI p‐value HR 95% CI P‐value
Female 0.85 0.68‐1.06 0.156 0.77 0.59‐1.02 0.063 0.97 0.74‐1.26 0.805
Age >75 y 1.05 0.75‐1.48 0.757 1.39 0.89‐2.16 0.147 1.54 0.99‐2.38 0.055
PS ECOG > 1 1.86 1.42‐2.44 <0.001 2.17 1.50‐3.13 <0.001 2.05 1.42‐2.96 <0.001
Right‐sided tumor 1.11 0.86‐1.43 0.407 0.96 0.71‐1.31 0.815 0.79 0.58‐1.08 0.135
Tumor grade 3 1.81 1.34‐2.45 <0.001 1.76 1.22‐2.55 0.003 1.65 1.15‐2.37 0.007
Primary tumor resected 1.04 0.60‐1.83 0.879 0.80 0.43‐1.49 0.480 1.48 0.83‐2.63 0.185
Synchronous metastases 0.70 0.55‐0.88 0.002 0.78 0.59‐1.04 0.087 0.77 0.58‐1.02 0.066
> 1 organ metastases 1.55 1.14‐2.10 0.005 1.79 1.22‐2.63 0.003 1.48 1.01‐2.16 0.044
Liver only 1.44 1.00‐2.08 0.051 1.44 0.92‐2.26 0.113 1.34 0.86‐2.09 0.198
Curative metastasis 
surgery
0.29 0.18‐0.47 <0.001 0.33 0.20‐0.55 <0.001 0.38 0.24‐0.62 <0.001
ALP high 2.00 1.57‐2.54 <0.001 1.95 1.45‐2.63 <0.001 1.59 1.48‐2.13 0.002
First‐line chemotherapy 0.38 0.27‐0.54 <0.001     ni     ni
MSI‐H 1.42 0.86‐2.37 0.174 2.34 1.18‐4.64 0.015 2.13 1.08‐4.18 0.028
BRAF mutation 1.86 1.29‐2.69 0.001 1.94 1.23‐3.05 0.004 1.62 1.04‐2.53 0.034
KRAS mutation 1.22 0.94‐1.57 0.135 1.39 1.02‐1.90 0.038 1.52 1.12‐2.08 0.008
Interactionsb                  
MSI‐H effect in wtBRAF 4.46 1.83‐10.86 0.001            
MSI‐H effect in 
mutBRAF
1.20 0.80‐1.80 0.386            
mutBRAF‐effect in MSS 1.44 1.14‐1.83 0.002            
mutBRAF‐effect in 
MSI‐H
0.40 0.16‐1.04 0.059            
Abbreviations: ALP high, Alkaline Phosphatase >105 U/L; CI, confidence interval; e, number of events; HR, hazard ratio; MSI‐H, microsatellite instable high; MSS, 
microsatellite stable; mutBRAF, BRAF mutated; n, number of patients; ni, not included; PS ECOG, performance status score developed by Eastern Cooperative 
Oncology Group; P‐value, from likelihood ratio test; wtBRAF, BRAF wildtype.
aCEA >4 and LDH high was also statistically significant when included in the multiple regression model, but were excluded from the analysis due to many missing 
values. 
bTesting the hypothesized interaction between MSI and BRAF showed significantly higher effect of MSI‐H among those with wtBRAF (HR = 4.46) than in those with 
mutBRAF (HR = 1.20) tumors and higher effect of mutBRAF among those with MSS (HR = 1.44) compared to MSI‐H (HR = 0.40) tumors (interaction HR = 0.28, 
95% CI: 0.11‐0.74, P = 0.010), after adjusting for all other covariates it was still statistically significant (interaction HR = 0.20, 95% CI: 0.94‐0.91, P = 0.037). 
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immunotherapy and BRAF‐inhibitor treatments. Our unse-
lected cohort of MSI‐H patients differed considerably from 
patients included in recent immunotherapy trials as they were 
older, had worse PS and most of them also had mutBRAF 
tumor (non‐Lynch). Further studies are needed to evaluate 
the effect of immunotherapy in these subgroups of patients. 
Patients with MSI‐H tumors had worse survival, very poor 
response rate and few received second‐line treatment, indi-
cating that these patients should probably be considered for 
immunotherapy as the first‐line treatment.
ACKNOWLEDGEMENTS
We thank Randi Eikeland (Haukeland University Hospital, 
Bergen, Norway) for data management.
CONFLICT OF INTEREST
The authors of this manuscript declare no potential conflicts 
of interest.
AUTHOR CONTRIBUTIONS
HS: conceptualization, data curation, methodology, project 
administration, supervision, writing—original draft and 
writing—review and editing.  PP: conceptualization, data 
curation, methodology, project administration, supervi-
sion and writing—review and editing. BG: conceptualiza-
tion, data curation, methodology, project administration, 
supervision, resources, writing—original draft and writ-
ing—review and editing. AD: investigation, methodology, 
validation and writing—review and editing.  FP: investi-
gation, methodology, resources, validation and writing—
review and editing.  PHE: investigation, methodology, 
validation and writing—review and editing. AM: investi-
gation, methodology, validation and writing—review and 
editing.  MS: investigation, methodology, validation and 
writing—review and editing. KA: formal analysis, visu-
alization, writing—original draft and writing—review and 
editing. GEE: formal analysis, methodology and writing—
review and editing.
ETHICS APPROVAL AND CONSENT TO 
PARTICIPATE
This study was performed in accordance with the Declaration 
of Helsinki. Written informed consent was obtained from all 
patients seen at the clinics. The study, including molecular 
classification of all tumors in the three regions, was approved 
by the regional ethical committees in Norway (Regional 
Committee for Medical and Health Research Ethics—REC 
West), Sweden (Regional Ethical Committee Uppsala) and 
Denmark (The Regional Scientific Ethical Committees for 
Southern Denmark).
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
ORCID
Kristine Ø. Aasebø   https://orcid.
org/0000-0003-3575-5588 
REFERENCES
 1. Muller CI, Schulmann K, Reinacher‐Schick A, et al. Predictive 
and prognostic value of microsatellite instability in patients 
with advanced colorectal cancer treated with a fluoropyrimi-
dine and oxaliplatin containing first‐line chemotherapy. A re-
port of the AIO Colorectal Study Group. Int J Colorectal Dis. 
2008;23(11):1033‐1039.
 2. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mis-
match repair system in patients with sporadic advanced colorectal 
cancer. Br J Cancer. 2009;100(2):266‐273.
 3. Smith CG, Fisher D, Claes B, et al. Somatic profiling of the epider-
mal growth factor receptor pathway in tumors from patients with 
advanced colorectal cancer treated with chemotherapy +/‐ cetux-
imab. Clin Cancer Res. 2013;19(15):4104‐4113.
 4. Fujiyoshi K, Yamamoto G, Takenoya T, et al. Metastatic 
Pattern of Stage IV Colorectal Cancer with High‐Frequency 
Microsatellite Instability as a Prognostic Factor. Anticancer Res. 
2017;37(1):239‐247.
 5. Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair 
status and BRAF mutation status in metastatic colorectal cancer 
patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and 
FOCUS studies. Clin Cancer Res. 2014;20(20):5322‐5330.
 6. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and micro-
satellite instability on the pattern of metastatic spread and prognosis 
in metastatic colorectal cancer. Cancer. 2011;117(20):4623‐4632.
 7. Sorbye H, Dragomir A, Sundstrom M, et al. High BRAF mutation 
frequency and marked survival differences in subgroups according 
to KRAS/BRAF mutation status and tumor tissue availability in a 
prospective population‐based metastatic colorectal cancer cohort. 
PLoS ONE. 2015;10(6):e0131046.
 8. Sorbye H, Cvancarova M, Qvortrup C, Pfeiffer P, Glimelius 
B. Age‐dependent improvement in median and long‐term sur-
vival in unselected population‐based Nordic registries of pa-
tients with synchronous metastatic colorectal cancer. Ann Oncol. 
2013;24(9):2354‐2360.
 9. Mol L, Koopman M, van Gils CW, Ottevanger PB, Punt CJ. 
Comparison of treatment outcome in metastatic colorectal can-
cer patients included in a clinical trial versus daily practice in The 
Netherlands. Acta Oncol. 2013;52(5):950‐955.
 10. Sinicrope FA. Lynch syndrome‐associated colorectal cancer. N 
Engl J Med. 2018;379(8):764‐773.
 11. de la Chapelle A, Hampel H. Clinical relevance of microsatellite in-
stability in colorectal cancer. J Clin Oncol. 2010;28(20):3380‐3387.
   | 3635AASEBØ Et Al.
 12. Popat S, Hubner R, Houlston RS. Systematic review of microsat-
ellite instability and colorectal cancer prognosis. J Clin Oncol. 
2005;23(3):609‐618.
 13. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite in-
stability as a biomarker for PD‐1 blockade. Clin Cancer Res. 
2016;22(4):813‐820.
 14. Kim CG, Ahn JB, Jung M, et al. Effects of microsatellite instability 
on recurrence patterns and outcomes in colorectal cancers. Br J 
Cancer. 2016;115(1):25‐33.
 15. Taieb J, Le Malicot K, Shi Q, et al. Prognostic value of BRAF and 
KRAS mutations in MSI and MSS stage III colon cancer. J Natl 
Cancer Inst. 2017;109(5).
 16. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associ-
ated with the BRAF V600E mutation in microsatellite‐stable colon 
cancers. Cancer Res. 2005;65(14):6063‐6069.
 17. Popovici V, Budinska E, Bosman FT, Tejpar S, Roth AD, Delorenzi 
M. Context‐dependent interpretation of the prognostic value of 
BRAF and KRAS mutations in colorectal cancer. BMC Cancer. 
2013;13:439.
 18. Le DT, Uram JN, Wang H, et al. PD‐1 blockade in tumors with mis-
match‐repair deficiency. N Engl J Med. 2015;372(26):2509‐2520.
 19. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in 
patients with metastatic DNA mismatch repair‐deficient or 
microsatellite instability‐high colorectal cancer (CheckMate 
142): an open‐label, multicentre, phase 2 study. Lancet Oncol. 
2017;18(9):1182‐1191.
 20. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical 
Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch 
Repair‐Deficient/Microsatellite Instability‐High Metastatic 
Colorectal Cancer. J Clin Oncol. 2018;JCO2017769901.
 21. Network NCC. NCCN Guidelines Colon Cancer (version 2.2018). 
https ://www.nccn.org/profe ssion als/physi cian_gls/pdf/colon.pdf. 
Accessed January 10, 2019.
 22. Uhlen M, Fagerberg L, Hallstrom BM, et al. Tissue‐based map of 
the human proteome. Science. 2015;347(6220):1260419.
 23. Kampf C, Olsson I, Ryberg U, SjostedtE, PontenF. Production of 
tissue microarrays, immunohistochemistry staining and digitaliza-
tion within the human protein atlas. J Vis Exp. 2012;63:3620.
 24. Goey KKH, Sorbye H, Glimelius B, et al. Consensus statement on 
essential patient characteristics in systemic treatment trials for met-
astatic colorectal cancer: Supported by the ARCAD Group. Eur J 
Cancer. 2018;100:35‐45.




val_1=1&advopt_preci sion=1&advopt_displ ay=1&showD ataFo 
r=race_1_and_age_range_1_and_stage_106_and_time_inter val_1. 
Accessed January 10, 2019.
 26. Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal 
cancer: The landscape of amplification and short variant mutations 
in ERBB2 and ERBB3. Cancer. 2018;124(7):1358‐1373.
 27. Winther SB, Liposits G, Skuladottir H, et al. Reduced-dose com-
bination chemotherapy (S-1 plus oxaliplatin) versus full-dose 
monotherapy (S-1) in older vulnerable patients with metastatic col-
orectal cancer (NORDIC9): a randomised, open-label phase 2 trial. 
Lancet Gastroenterol Hepatol. 2019;4(5):376‐388.
 28. French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of 
defective mismatch repair and BRAF V600E in patients with colon 
cancer. Clin Cancer Res. 2008;14(11):3408‐3415.
 29. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability 
and BRAF mutation testing in colorectal cancer prognostication. J 
Natl Cancer Inst. 2013;105(15):1151‐1156.
 30. Cohen R, Buhard O, Cervera P, Hain E, Dumont S, Bardier A, 
et al. Clinical and molecular characterisation of hereditary and 
sporadic metastatic colorectal cancers harbouring microsatel-
lite instability/DNA mismatch repair deficiency. Eur J Cancer. 
2017;86:266‐274.
 31. Pietrantonio F, Di Nicolantonio F, Schrock AB, et al. ALK, ROS1, 
and NTRK rearrangements in metastatic colorectal cancer. J Natl 
Cancer Inst. 2017;109(12).
 32. Seppala TT, Bohm JP, Friman M, et al. Combination of microsatel-
lite instability and BRAF mutation status for subtyping colorectal 
cancer. Br J Cancer. 2015;112(12):1966‐1975.
 33. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular 
subtypes of colorectal cancer. Nat Med. 2015;21(11):1350‐1356.
 34. Kugel CH III, Douglass SM, Webster MR, et al. Age correlates 
with response to anti‐PD1, reflecting age‐related differences in in-
tratumoral effector and regulatory T‐cell populations. Clin Cancer 
Res. 2018;24(21):5347‐5356.
 35. Lenz HJJ, Van Cutsem E, Limon ML, et al. LBA18_PRDurable 
clinical benefit with nivolumab (NIVO) plus low‐dose ipilimumab 
(IPI) as first‐line therapy in microsatellite instability‐high/mis-
match repair deficient (MSI‐H/dMMR) metastatic colorectal cancer 
(mCRC). Ann Oncol. 2018;29(suppl_8):mdy424.019‐mdy424.019.
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section at the end of the article. 
How to cite this article: Aasebø KØ, Dragomir A, 
Sundström M, et al. Consequences of a high incidence 
of microsatellite instability and BRAF‐mutated 
tumors: A population‐based cohort of metastatic 
colorectal cancer patients. Cancer Med. 2019;8:3623–
3635. https ://doi.org/10.1002/cam4.2205
